Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia

Neuropsychopharmacology

Volumn 28, Issue 8, 2003, Pages 1506-1514

  Todorova, Valentina K ^a   Elbein, Alan D ^a   Kyosseva, Svetlana V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

c Jun; Cerebellum; MAPK ERK; Post mortem; Schizophrenia; Transcription

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROLEPTIC AGENT; PROTEIN B JUN; PROTEIN C JUN; PROTEIN D JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CADAVER; CEREBELLUM VERMIS; CONTROLLED STUDY; GENE; GENE TARGETING; HUMAN; HUMAN TISSUE; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; ADULT; AGED; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; CEREBELLUM; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; CEREBELLUM; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 0041884818     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300211     Document Type: Article

References (69)

1. Allen G, Buxton RB, Wong EC, Courchesne E (1997). Attentional activation of the cerebellum independent of motor involvement. Science 275: 1940-1943.
2. Anderson AJ, Cummings BJ, Cotman CW (1994). Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology. Exp Neurol 125: 286-295.
3. Anderson AJ, Su H, Cotman CW (1996). DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 16: 1710-1719.
4. Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Ponto LL et al (1996). Schizophrenia and cognitive dysmetria: a PET study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci 93: 9985-9990.
5. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Ponto LL et al (1997). Hypofrontality in schizophrenia: disturbed dysfunctional circuits in neuroleptic naïve patients. Lancent 349: 1730-1734.
6. Avissar S, Barki-Harrington L, Nechamkin Y, Roitman G, Schreiber G (2001). Elevated dopamine receptor-coupled G(s) protein measures in mononuclear leukocytes of patients with schizophrenia. Schizophr Res 47: 37-47.
7. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P (2000). Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 24: 881-887.
8. Bernstein HG, Krell D, Braunewell KH, Baumann B, Gundelfinger ED, Diekmann S et al (2001). Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol 60: 661-670.
9. Berrettini WH (2000). Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry 48: 531-538.
10. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science 286: 1358-1362.
11. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD et al (1991). ERKs: a family of protein-serine/treonine kinases that are activated and tyrosine phosphorylated in responses to insulin and NGF. Cell 65: 663-675.
12. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z (2001). Differential regulation of mitogen-activated protein kinases ERK1/ERK2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21: 434-443.
13. Coyle JT (1996). The glutamatergic hypothesis for schizophrenia. Harvard Rev Psychiatry 3: 241-253.
14. Dragunow M (1996). A role for immediate-early transcription factors in learning and memory. Behav Genet 26: 293-299.
15. Duman RS, Malberg J, Thome J (1999). Neural plasticity and antidepressant treatment. Biol Psychiatry 46: 1181-1191.
16. 2A receptors in the human cerebellum and alterations in schizophrenia. Synapse 42: 104-114.
17. Eastwood SL, Cotter D, Harrison PJ (2001b). Cerebellar synaptic protein expression in schizophrenia. Neuroscience 105: 219-229.
18. Fiore RS, Murphy TH, Sanghera JS, Pelech SL, Baraban JM (1993). Activation of p42 mitogen-activated protein kinase by glutamate receptor stimulation in rat primary cortical cultures. J Neurochem 61: 1626-1633.
19. Guidotti A, Auta J, Davis JM, Geverini V, Dwivedi Y, Grayson DR et al (2001). Decrease in reelin and glutamic acid decarboxylase 67 (GAD) 67 expression in schizophrenia and bipolar disorder. Arch Gen Psychiatry 57: 1061-1069.
20. Herdegen T, Leah JD (1998). Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Rev 27: 370-490.
21. Hussain N, Flumerfelt BA, Rajakumar N (2001). Glutamatergic regulation of haloperidol-induced c-fos expression in rat striatum and nucleus accumbens. Neuroscience 102: 391-399.
22. Ichimiya T, Okubo Y, Suhara T, Sudo Y (2001). Reduced volume of the cerebellar vermis in neuroleptic-naïve schizophrenia. Biol Psychiatry 49: 20-27.
23. Jacobsen LK, Giedd JN, Berquin PC, Krain AL, Hamburger SD, Kumra S et al (1997). Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Am J Psychiatry 154: 1663-1669.
24. Kaplan DR, Miller FD (2000). Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10: 381-391.
25. Karson CN, Griffin WST, Mrak RE, Husain M, Dawson TM, Snyder SH et al (1996). Nitric oxide synthase (NOS) in schizophrenia. Increase in cerebellar vermis. Mol Chem Neuropathol 27: 275-284.
26. Katsetos CD, Hyde TM, Herman MM (1997). Neuropathology of the cerebellum in schizophrenia - and update: 1996 and future directions. Biol Psychiatry 42: 213-224.
27. Kontkanen O, Lakso M, Wong G, Castren E (2002). Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 27: 152-162.
28. Kurino M, Fukunaga K, Ushio Y, Miyamoto E (1995). Activation of mitogen-activated protein kinase in cultured rat hippocampal neurons by stimulation of glutamate receptors. J Neurochem 65: 1282-1289.
29. Kyosseva SV, Elbein AD, Griffin WST, Mrak RE, Lyon L, Karson CN (1999). Mitogen-activated protein kinases in schizophrenia. Biol Psychiatry 46: 689-696.
30. Kyosseva SV, Elbein AD, Hutton TL, Griffin WS, Mrak RE, Sturner WQ et al (2000). Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. Arch Gen Psychiatry 57: 685-691.
31. Kyosseva SV, Owens SM, Elbein AD, Karson CN. (2001). Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain. Neuropsychopharmacology 24: 267-277.
32. Labudova O, Krapfenbauer K, Moenkemann H, Rink H, Kitzmuller E, Cairns N et al (1998). Decreased transcription factor jun D in brains of patients with Down syndrome. Neurosci Lett 252: 159-162.
33. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S et al (2000). Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20: 4011-4020.
34. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE et al (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44: 1099-1117.
35. Loeber RT, Gruber SA, Cohen BM, Renshaw PF, Sherwood AR, Yurgelun-Todd DA (2002). Cerebellar blood volume in bipolar patients correlates with medication. Biol Psychiatry 51: 370-376.
36. MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RL, Synek B et al (1997). Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. Exp Neurol 147: 316-332.
37. Marcus DL, Strafaci JA, Miller DC, Masia S, Thomas CG, Rosman J et al (1998). Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging 19: 393-400.
38. Martin P, Albers M (1995). Cerebellum and schizophrenia: a selective review. Schizophr Bull 21: 241-250.
39. Martin G, Segui J, Diaz-Villoslada P, Montalban X, Planas AM, Ferre I (1996). Jun expression is found in neurons located in the vicinity of subacute plaques in patients with multiple sclerosis. Neurosci Lett 212: 95-98.
40. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106S-115S.
41. Middleton FA, Strick PL (1994). Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science 266: 458-461.
42. Middleton FA, Strick PL (1998). Cerebellar output: motor and cognitive channels. Trends Cognit Sci 2: 338-347.
43. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6: 293-301.
44. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
45. Morgan JI, Curran T (1991). Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14: 421-451.
46. Mukaetova-Ladinska EB, Hurt J, Honer WG, Harrington CR, Wischik CM (2001). Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci Lett 317: 161-165.
47. 3H]cAMP binding sites and decrease in Giα and Goα immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res 615: 41-49.
48. Nopoulos PC, Ceilley JW, Gailis EA, Andreasen NC (1999). An MRI study of cerebellar vermis morphology in patients with schizophrenia: evidence in support of the 'cognitive dysmetria'. Biol Psychiatry 46: 703-711.
49. Nopoulos PC, Ceilley JW, Gailis EA, Andreasen NC (2001). An MRI study of midbrain morphology in patients with schizophrenia: relationship to psychosis, neuroleptics, and cerebellar neural circuitry. Biol Psychiatry 49: 13-19.
50. o) in the basal ganglia of control and schizophrenic brain. J Neural Transm (Gen Sect) 79: 227-234.
51. o) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J Neural Transm (Gen Sect) 84: 147-153.
52. Okada F, Tokumitsu Y, Takahashi N, Crow TJ, Roberts GW (1994). Reduced concentrations of the α subunit of GTP-binding protein Go in schizophrenic brain. J Neural Transm (Gen Sect) 95: 95-104.
53. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
54. Paradiso S, Andreasen N, O'Leary D, Arndt S, Robinson R (1997). Cerebellar size and cognition: correlations with IQ, verbal memory, and motor dexterity. Neuropsychiatry Neuropsychol Behav Neurol 10: 1-8.
55. Pennypacker KR (1995). AP-1 transcription factor complexes in CNS disorders and development. J Fla Med Assoc 82: 551-554.
56. Punts A, Wey E, Jostarndt K, Vogt M, Wittwer M, Widmer HR et al (1998). Expression of fos and jun genes in human skeletal muscle after exercise. Am J Physiol 274: C129-C137.
57. Rapoport M, van Reekum R, Mayberg H (2000). The role of the cerebellum in cognition and behavior: a selective review. J Neuropsychiatry Clin Neurosci 12: 193-198.
58. Salzman S, Endicott J, Clayton P, Winokur G (eds) (1983). Diagnostic Evaluation After Death (DEAD). National Institute of Mental Health Neuroscience Research Branch: Rockville, MD.
59. Schmahmann JD (1998). Dysmetria of thought: clinical consequences of cerebellar dysfunction on cognition and affect. Trends Cognit Sci 2: 362-371.
60. Soares JC, Mann JJ (1997). The anatomy of mood disorders - review of structural neuroimaging studies. Biol Psychiatry 41: 86-106.
61. Svensson TH (2000). Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Rev 31: 320-329.
62. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K et al (2000). Abnormal expression of brain-derived neurotrophic factor and its receptor in the cortico-limbic system of schizophrenic patients. Mol Psychiatry 5: 293-300.
63. Tran KD, Smutzer GS, Doty RL, Arnold SE (1998). Reduced Purkinje cell size in the cerebellar vermis of elderly patients with schizophrenia. Am J Psychiatry 155: 1288-1290.
64. Vanhoutte P, Barnier JV, Guibert B, Pages C, Besson MJ, Hipskind RA et al (1999). Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via and extracellular signal-regulated kinase-dependent pathway in brain slices. Mol Cell Biol 19: 136-146.
65. Wassink TH, Andreasen NC, Nopoulos P, Flaum M (1999). Cerebellar morphology as a predictor of symptom and psychosocial outcome in schizophrenia. Biol Psychiatry 45: 41-48.
66. Weinberger DR, Kleinman JE, Luchins DJ, Bigelow LB, Wyatt RJ (1980). Cerebellar pathology in schizophrenia: a controlled postmortem study. Am J Psychiatry 137: 359-561.
67. Whitmarsh AJ, Davis RJ (1996). Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74: 589-607.
68. Xia Z, Dudek H, Miranti CK, Greenberg ME (1996). Calcium influx via NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci 16: 5425-5436.
69. Yang CQ, Kitamura N, Nishino N, Shirakawa O, Nakai H (1998). Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol Psychiatry 43: 12-19.